- In May 2024, the Global Health Innovative Technology (GHIT) Fund announced an investment of approximately JPY 1.64 billion (USD 10.8 million) aimed at advancing four projects focused on developing new treatments for malaria and neglected tropical diseases. This funding initiative highlights the organization's commitment to addressing critical health challenges in underserved regions. By supporting innovative drug development, GHIT aims to enhance therapeutic options and improve health outcomes for affected populations worldwide
- In May 2023, Astellas Pharma Inc. announced its commitment to the Global Health Innovative Technology Fund, which aims to support the development of medications, diagnostic tools, and vaccines targeted at combating various infectious diseases. This contribution focuses particularly on underrecognized tropical diseases that often lack sufficient funding and resources. By investing in this initiative, Astellas Pharma seeks to enhance global health outcomes and address critical gaps in infectious disease management
- In July 2022, Mylab Discovery Solutions introduced its innovative disease testing kit, the 'PathoDetect Extended Monsoon Fever Panel,' which showcased impressive sensitivity and specificity. This advanced panel effectively differentiates between several infectious diseases, including malaria, chikungunya, dengue, Zika, leptospirosis, salmonellosis bacterial species, and the leishmaniasis parasite. With its ability to accurately identify multiple pathogens, this testing kit enhances diagnostic capabilities during the monsoon season, addressing critical health challenges in affected regions
- In November 2021, Achico, a Swiss healthcare technology firm, announced the development of diagnostic kits specifically for dengue fever. These innovative test kits leverage the company’s DNA aptamer technology platform, which has proven to be effective in diagnosing COVID-19. By applying this advanced technology to dengue diagnostics, Achico aims to enhance the accuracy and efficiency of testing for this significant infectious disease
- In November 2021, Swiss healthcare technology company Achico unveiled its plans to develop diagnostic kits for dengue fever. These innovative testing kits will utilize the company's DNA aptamer technology platform, which has already demonstrated its effectiveness in diagnosing COVID-19. This advancement aims to enhance the diagnostic capabilities for dengue fever, addressing the growing need for reliable testing solutions
Frequently Asked Questions
The market is segmented based on Global Arthropod-Borne Viral Infections Testing Market Segmentation, By Test Type (Molecular Tests, Cultural Tests, Immunoassays, and Others), End User (Hospitals, Research Centers, and Diagnostic Centers) – Industry Trends and Forecast to 2031
.
The Global Arthropod Borne Viral Infections Testing Market size was valued at USD 1.14 USD Billion in 2023.
The Global Arthropod Borne Viral Infections Testing Market is projected to grow at a CAGR of 5.65% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
